EuBiologics signs ₩10.5bn oral cholera vaccine supply contract with UNICEF
EuBiologics filed a supply contract to supply its oral cholera vaccine (Euvichol-S) to UNICEF, with a contract amount of ₩10.5bn. The contract period runs from Oct 23, 2026 to Jan 31, 2027, and the amount is 7.0% of revenue as reported.
Key facts
| Contract name | Oral cholera vaccine (Euvichol-S) supply |
|---|---|
| Counterparty | UNICEF |
| Contract amount | ₩10.5bn |
| % of revenue (as reported) | 7.0% |
| Period start | Oct 23, 2026 |
| Period end | Jan 31, 2027 |
Comparison
| Amount as % of FY2025 revenue (calculated) | 7.0% |
|---|---|
| Revenue 2025 | ₩149.2bn |
| Revenue 2024 | ₩96.0bn |
| Revenue 2023 | ₩69.4bn |
Context
In the 12 months before this filing, EuBiologics filed 5 supply contracts totaling ₩69.1bn, all with UNICEF.
Key metrics
Supply contracts
| Supply contracts, last 12 months | ₩79.6bn |
|---|---|
| Supply contracts vs prior-year revenue | 53.3% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗